Menu
Safely and well informed
Company profile
Business description
HAEMATO froup is active in the pharmaceutical sector as a manufacturer and wholesaler. The focus of its business activities is on innovative therapies and the expansion of business in the lifestyle and aesthetics sector. In the area of innovative therapies, HAEMATO specialises in five major therapeutic areas with its product portfolio: oncology, rheumatology, neurology, HIV/AIDS and ophthalmology. Furthermore, privately financed products for aesthetic treatments are also part of the portfolio.
Company Information
First trading day
10.05.1993
Accounting standard
HGB / IFRS
End of financial year
31.12.
Management Board
Patrick Brenske
Attila Strauss
Supervisory Board
Andrea Grosse, Chairwoman of the Supervisory Board
Prof. Dr. Dr. Sabine Meck, Deputy Chairwoman of the Supervisory Board
Uwe Zimdars, Member of the Supervisory Board
Key financial figures
The most important key figures at a glance (in TEUR)
|
|
2022
|
2021
|
2020
|
2019
|
2018
|
2015
|
2010
|
|---|---|---|---|---|---|---|---|
| Balance sheet total | 176.570 | 182,010 | 169,058 | 128,567 | 116,516 | 106,989 | 36,541 |
| Equity | 147.168 | 144,726 | 125,480 | 72,218 | 75,676 | 58,289 | 12,323 |
| Equity ratio | 83,3 % | 79.5 % | 74.2 % | 56.2 % | 64.9 % | 54.5 % | 34 % |
| Sales revenue | 248.142 | 285,043 | 238,333 | 197,834 | 274,120 | 229,727 | 6,958 |
| EBIT | 8.295 | 11,162 | 1,627 | -19 | 8,503 | 8,223 | 1,569 |
| Net profit for the year | 8.193 | 6,534 | -4,831 | -1,172 | 6,276 | 5,540 | 1,579 |
| Balance sheet profit | 29.459 | 27,017 | 22,256 | 27,086 | 30,544 | 24,646 | 2,423 |